Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26
- October 24, 2025 - Rose Pharma Inc., a clinical-stage biopharmaceutical company developing ROSE-010, a rapid-onset, short-duration GLP-1 therapy targeting both weight management and acute IBS pain, today announced that Chief Executive Officer Enda Kenny, PhD will present data from its recent clinical trial in weight management at #ObesityWeek2025 (sponsored by The Obesity Society) on Tuesday, November 4, 2025 at 7:30 p.m
Lactobacillus salivarius Subspecies salicinius SA-03 is a New Probiotic Capable of Enhancing Exercise Performance and Decreasing Fatigue
Adequate protein intake and resistance training help preserve and build lean muscle mass during weight loss
Thats how they work
Learn how high-fat foods impact digestion with GLP-1s & discover smart dietary choices to minimize side effects
US$ 20.26
US$ 23.32
US$ 25.53
